Myungmoon Pharmaceutical Rises 11.59% Amid Deworming Drug (Fenbendazole, etc.) Theme Uptrend

On the 22nd, the anthelmintic (including Fenbendazole) theme rose by 3.45% compared to the previous day, showing strength, while Myungmoon Pharmaceutical, which is attracting attention as a related stock, surged by 11.59% compared to the previous day. Myungmoon Pharmaceutical is known as a comprehensive pharmaceutical company focused on prescription drugs.

[Graph] Major stock price changes in the anthelmintic (including Fenbendazole) theme



According to provisional data compiled at 13:11, foreigners sold a net 111,000 shares of Myungmoon Pharmaceutical, indicating a large net sell-off by foreign investors.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)



According to the analysis by Thinkpool Robo Algorithm RASSI, Myungmoon Pharmaceutical’s quant financial score is 5.14 points, which is lower in stability, profitability, and growth compared to the average of other stocks related to the anthelmintic (including Fenbendazole) theme. This can be interpreted as Myungmoon Pharmaceutical having relatively low investment attractiveness from a financial perspective compared to other stocks. On the other hand, Aliko Pharmaceutical ranked first in quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top financial scores within the theme


※ The quant financial score is the result of the Robo Algorithm analyzing each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.